Premium
CLINICAL EVALUATION OF LOCAL ANESTHETICS. VII. CITANEST®
Author(s) -
Bonica John J.,
Englesson Sören,
O'Keefe Anthony
Publication year - 1965
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1965.tb00542.x
Subject(s) - medicine , potency , clinical trial , anesthesia , significant difference , toxicity , statistical analysis , clinical practice , drug , pharmacology , physical therapy , biochemistry , chemistry , statistics , mathematics , in vitro
SUMMARY A clinical trial evaluating 2% Citanest with 2% Xylocaine was undertaken and completed in 115 cases. Analysis of the data revealed that there is no statistically significant difference between these two drugs in regard to latency, potency, and penetrance. The data on duration of anesthesia were not sufficient to permit statistical analysis, but observations indicate that there is no significant difference between the two drugs. No local or systemic side effects or reactions were noted with either drug. On the basis of these data and those of others, it is concluded that Citanest is as effective, safe and clinically useful as Xylocaine, and probably superior because of lower toxicity. For this reason, it is recommended that Citanest be investigated further and, if the prior studies on toxicity are corroborated, it should be used widely in clinical practice.